FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170232908> ?p ?o ?g. }

• W3170232908 abstract "About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML patients. Monotherapy, while efficacious, shows short-lived responses, highlighting the need for combination therapies. Here we show that gilteritinib and CUDC-907, a dual inhibitor of PI3K and histone deacetylases, synergistically induce apoptosis in FLT3-ITD AML cell lines and primary patient samples and have striking in vivo efficacy. Upregulation of FLT3 and activation of ERK are mechanisms of resistance to gilteritinib, while activation of JAK2/STAT5 is a mechanism of resistance to CUDC-907. Gilteritinib and CUDC-907 reciprocally overcome these mechanisms of resistance. In addition, the combined treatment results in cooperative downregulation of cellular metabolites and persisting antileukemic effects. CUDC-907 plus gilteritinib shows synergistic antileukemic activity against FLT3-ITD AML in vitro and in vivo, demonstrating strong translational therapeutic potential." @default.
• W3170232908 created "2021-06-22" @default.
• W3170232908 creator A5000948146 @default.
• W3170232908 creator A5008374158 @default.
• W3170232908 creator A5010440853 @default.
• W3170232908 creator A5012677271 @default.
• W3170232908 creator A5018943067 @default.
• W3170232908 creator A5025185954 @default.
• W3170232908 creator A5030245240 @default.
• W3170232908 creator A5032764121 @default.
• W3170232908 creator A5033308534 @default.
• W3170232908 creator A5033632697 @default.
• W3170232908 creator A5045242838 @default.
• W3170232908 creator A5052096952 @default.
• W3170232908 creator A5052787170 @default.
• W3170232908 creator A5061036650 @default.
• W3170232908 creator A5065869973 @default.
• W3170232908 creator A5084102458 @default.
• W3170232908 creator A5087943411 @default.
• W3170232908 date "2021-06-07" @default.
• W3170232908 modified "2023-10-07" @default.
• W3170232908 title "The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML" @default.
• W3170232908 cites W1159008209 @default.
• W3170232908 cites W1569244981 @default.
• W3170232908 cites W1969130273 @default.
• W3170232908 cites W1983420428 @default.
• W3170232908 cites W1986938005 @default.
• W3170232908 cites W1990408342 @default.
• W3170232908 cites W2003930446 @default.
• W3170232908 cites W2004639735 @default.
• W3170232908 cites W2005909927 @default.
• W3170232908 cites W2006067987 @default.
• W3170232908 cites W2017059819 @default.
• W3170232908 cites W2030292335 @default.
• W3170232908 cites W2041230280 @default.
• W3170232908 cites W2048339949 @default.
• W3170232908 cites W2055255976 @default.
• W3170232908 cites W2060794068 @default.
• W3170232908 cites W2074873270 @default.
• W3170232908 cites W2076752985 @default.
• W3170232908 cites W2086404440 @default.
• W3170232908 cites W2103562758 @default.
• W3170232908 cites W2107277218 @default.
• W3170232908 cites W2117303613 @default.
• W3170232908 cites W2117551758 @default.
• W3170232908 cites W2123727748 @default.
• W3170232908 cites W2124966133 @default.
• W3170232908 cites W2128841304 @default.
• W3170232908 cites W2129915570 @default.
• W3170232908 cites W2140277032 @default.
• W3170232908 cites W2167789626 @default.
• W3170232908 cites W2172697812 @default.
• W3170232908 cites W2235360349 @default.
• W3170232908 cites W2253202562 @default.
• W3170232908 cites W2317505970 @default.
• W3170232908 cites W2526397866 @default.
• W3170232908 cites W2558945204 @default.
• W3170232908 cites W2587614259 @default.
• W3170232908 cites W2620653306 @default.
• W3170232908 cites W2654449699 @default.
• W3170232908 cites W2752305310 @default.
• W3170232908 cites W2771708376 @default.
• W3170232908 cites W2775521721 @default.
• W3170232908 cites W2775864650 @default.
• W3170232908 cites W2781525129 @default.
• W3170232908 cites W2793968158 @default.
• W3170232908 cites W2797261189 @default.
• W3170232908 cites W2803962537 @default.
• W3170232908 cites W2883474345 @default.
• W3170232908 cites W2891248360 @default.
• W3170232908 cites W2916665060 @default.
• W3170232908 cites W2963518684 @default.
• W3170232908 cites W2982353618 @default.
• W3170232908 cites W3119005666 @default.
• W3170232908 doi "https://doi.org/10.1038/s41408-021-00502-7" @default.
• W3170232908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8184771" @default.
• W3170232908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34099621" @default.
• W3170232908 hasPublicationYear "2021" @default.
• W3170232908 type Work @default.
• W3170232908 sameAs 3170232908 @default.
• W3170232908 citedByCount "17" @default.
• W3170232908 countsByYear W31702329082021 @default.
• W3170232908 countsByYear W31702329082022 @default.
• W3170232908 countsByYear W31702329082023 @default.
• W3170232908 crossrefType "journal-article" @default.
• W3170232908 hasAuthorship W3170232908A5000948146 @default.
• W3170232908 hasAuthorship W3170232908A5008374158 @default.
• W3170232908 hasAuthorship W3170232908A5010440853 @default.
• W3170232908 hasAuthorship W3170232908A5012677271 @default.
• W3170232908 hasAuthorship W3170232908A5018943067 @default.
• W3170232908 hasAuthorship W3170232908A5025185954 @default.
• W3170232908 hasAuthorship W3170232908A5030245240 @default.
• W3170232908 hasAuthorship W3170232908A5032764121 @default.
• W3170232908 hasAuthorship W3170232908A5033308534 @default.
• W3170232908 hasAuthorship W3170232908A5033632697 @default.
• W3170232908 hasAuthorship W3170232908A5045242838 @default.
• W3170232908 hasAuthorship W3170232908A5052096952 @default.
• W3170232908 hasAuthorship W3170232908A5052787170 @default.
• W3170232908 hasAuthorship W3170232908A5061036650 @default.
• W3170232908 hasAuthorship W3170232908A5065869973 @default.

• next